Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 7;13:1159–1170. doi: 10.2147/OTT.S232354

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Ma et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The overexpression of PCAT6 alleviates the inhibitory effects of miR-543 accumulation on the proliferation, metastasis and chemoresistance and the promoting effect on the apoptosis of CC cells. CC cells transfected with miR-NC, miR-543, miR-543 + Vector or miR-543 + PCAT6 were used for the following experiments. (A) The abundance of miR-543 was measured in CC cells by qRT-PCR. (B and C) MTT assay was carried out to detect the proliferation of CC cells. (D) Flow cytometry was performed to determine the apoptosis of CC cells. (E and F) Western blot assay was conducted to measure the abundance of Bcl-2 and cleaved-caspase 3 in CC cells. (G and H) Transwell migration and invasion assays were conducted in CC cells, and the number of migration and invasion cells was counted. (I and J) Cell viability was detected in the above CC cells treated with cisplatin at a concentration of 12.5, 25, 50, 100 or 200 μM. *P<0.05.